$62.35
0.17%
Nasdaq, Apr 21, 09:17 pm CET
ISIN
US2183521028
Symbol
CORT

Corcept Therapeutics Incorporated. Stock price

$62.24
+4.36 7.53% 1M
+15.07 31.95% 6M
+11.85 23.52% YTD
+39.24 170.61% 1Y
+38.98 167.58% 3Y
+49.60 392.41% 5Y
+56.28 944.30% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-2.36 3.65%
ISIN
US2183521028
Symbol
CORT
Sector
Industry

Key metrics

Market capitalization $6.57b
Enterprise Value $6.19b
P/E (TTM) P/E ratio 50.47
EV/FCF (TTM) EV/FCF 31.60
EV/Sales (TTM) EV/Sales 9.17
P/S ratio (TTM) P/S ratio 9.73
P/B ratio (TTM) P/B ratio 9.63
Revenue growth (TTM) Revenue growth 39.94%
Revenue (TTM) Revenue $675.04m
EBIT (operating result TTM) EBIT $136.95m
Free Cash Flow (TTM) Free Cash Flow $195.90m
Cash position $383.33m
EPS (TTM) EPS $1.23
P/E forward 36.72
P/S forward 7.25
EV/Sales forward 6.84
Short interest 21.93%
Show more

Is Corcept Therapeutics Incorporated. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Corcept Therapeutics Incorporated. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

Buy
100%

Financial data from Corcept Therapeutics Incorporated.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
675 675
40% 40%
100%
- Direct Costs 11 11
68% 68%
2%
664 664
40% 40%
98%
- Selling and Administrative Expenses 279 279
53% 53%
41%
- Research and Development Expense 247 247
34% 34%
37%
138 138
26% 26%
20%
- Depreciation and Amortization 1.34 1.34
42% 42%
0%
EBIT (Operating Income) EBIT 137 137
28% 28%
20%
Net Profit 140 140
32% 32%
21%

In millions USD.

Don't miss a Thing! We will send you all news about Corcept Therapeutics Incorporated. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Corcept Therapeutics Incorporated. Stock News

Neutral
Business Wire
about 8 hours ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the publication of findings from the prevalence phase of the CATALYST trial in D...
Positive
Seeking Alpha
6 days ago
Corcept is transitioning from a single-product company to a multi-product, multi-market Platform Growth™ company, promising rapid revenue and earnings growth. Relacorilant's success in platinum-resistant ovarian cancer and potential FDA approval for hypercortisolism could significantly boost Corcept's market presence and revenue. Corcept's expanding pipeline includes promising treatments for pr...
Negative
MarketBeat
11 days ago
With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be looking for an opportunity. While it's true that some of the biggest firms in the world started April with major share price discounts, investors may want to find companies to target that have been mor...
More Corcept Therapeutics Incorporated. News

Company Profile

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Head office United States
CEO Joseph Belanoff
Employees 500
Founded 1998
Website www.corcept.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today